Genmab A/S (GNMSF)
OTCMKTS · Delayed Price · Currency is USD
297.22
0.00 (0.00%)
Oct 22, 2025, 8:00 PM EDT
Genmab Employees
Genmab had 2,682 employees as of December 31, 2024. The number of employees increased by 478 or 21.69% compared to the previous year.
Employees
2,682
Change (1Y)
478
Growth (1Y)
21.69%
Revenue / Employee
$1,381,918
Profits / Employee
$519,476
Market Cap
18.32B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2,682 | 478 | 21.69% |
| Dec 31, 2023 | 2,204 | 544 | 32.77% |
| Dec 31, 2022 | 1,660 | 448 | 36.96% |
| Dec 31, 2021 | 1,212 | 431 | 55.19% |
| Dec 31, 2020 | 781 | 233 | 42.52% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| American Oncology Network | 1,914 |
| Jushi Holdings | 1,234 |
| Glass House Brands | 374 |
| Silence Therapeutics | 116 |
| Elite Pharmaceuticals | 68 |
| Northwest Biotherapeutics | 25 |
| QT Imaging Holdings | 21 |
| CytoDyn | 13 |
Genmab News
- 2 days ago - Merus Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS - Business Wire
- 5 days ago - Why Is Genmab Stock Trading Lower On Monday? - Benzinga
- 5 days ago - Why Is Genmab Stock Trading Lower On Monday? - Benzinga
- 5 days ago - Genmab (GMAB) Shares Drop Over 6% Amid Market Volatility - GuruFocus
- 5 days ago - Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
- 6 days ago - Genmab (GMAB) Reports Promising Results from RAINFOL-01 Trial - GuruFocus
- 7 days ago - Genmab's Rina-S Achieves 50% Response Rate In Advanced Endometrial Cancer Trial - Nasdaq
- 8 days ago - Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer - GlobeNewsWire